吉華集團(603980.SH):利斯的明透皮貼劑獲得藥品註冊證書
格隆匯6月13日丨吉華集團(603980.SH)公佈,下屬控股子公司江蘇康倍得藥業股份有限公司(簡稱“康倍得”)同時收到國家藥品監督管理局覈準簽發的兩項利斯的明透皮貼劑《藥品註冊證書》。利斯的明(Rivastigmine)是一種可逆性膽鹼酯酶抑制劑,其透皮貼劑劑型由諾華公司(Novartis)原研開發,於2007年首次獲得美國FDA批準上市,主要用於治療輕至中度阿爾茨海默病(Alzheimer'sdisease,AD)。該產品於2017年經國家藥品監督管理局(NMPA)批準中國上市,爲國內阿爾茨海默病患者提供了重要的非口服給藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.